DURHAM, N.C., Nov. 11, 2010 /PRNewswire/ -- Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present a corporate overview and the next steps in the clinical development of Argos' Arcelis™ immunotherapy at the Lazard Capital Markets 7th Annual Healthcare Conference in New York at 11 a.m. EST on Wednesday, Nov. 17, 2010. The conference will take place at The St. Regis New York.
Argos is in the process of securing funding to begin a Phase 3 trial in renal cell carcinoma (RCC) with its Arcelis immunotherapy, AGS 003, in mid-2011. The company recently presented favorable progression-free survival and safety results from an ongoing Phase 2 trial for AGS 003 in combination with sunitinib. Argos' Arcelis HIV program, AGS-004, is also currently being tested in a double-blind, placebo controlled, randomized Phase 2b study co-funded by the NIH to further demonstrate that it is a feasible treatment option of HIV-1 infected patients.
About the Arcelis™ Technology
Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.
About Argos Therapeutics, Inc.Argos is an immunotherapy c
|SOURCE Argos Therapeutics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved